News Articles

02/28/2019

Design, Optimization, and Multisite Evaluation of a Targeted Next-Generation Sequencing Assay System for Chimeric RNAs from Gene Fusions and Exon-Skipping Events in Non–Small Cell Lung Cancer

Lung cancer accounts for approximately 14% of all newly diagnosed cancers and is the leading cause of cancer-related deaths. Chimeric RNA resulting from gene fusions (RNA fusions) and other RNA splicing errors are driver events and clinically addressable targets for non–small cell lung cancer (NSCLC).

01/24/2019

SeraCare partners with AccuRef, Bayer

SeraCare Life Sciences announced an exclusive partnership with AccuRef Diagnostics, a division of Applied StemCell, to market and sell AccuRef’s portfolio of CRISPR-engineered cell line reference materials alongside the Seraseq portfolio of NGS cancer products.

12/10/2018

SeraCare Acquired by LGC

Manufacturer of quality control materials SeraCare Life Sciences has been acquired by LGC, an international life sciences measurement and testing company, strengthening LGC’s position in the clinical quality control tools market.

11/05/2018

SeraCare NTRK Reference Material Panel

SeraCare Life Sciences has announced the commercial launch of an expanded neurotrophic tropomyosin receptor kinase (NTRK) RNA fusion material panel developed in partnership with Bayer.

06/07/2018

New ctDNA reference materials for NGS

SeraCare Life Sciences is adding ct­DNA Complete and ctDNA Panels to its circulating tumor DNA portfolio of reference materials. These new materials expand the Seraseq product line to also cover copy number variations and accelerate single-gene and variant-focused testing.

01/08/2018

SeraCare Life Sciences Announces Joe Bernardo as New Company Chairman

SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, today announced that Joe Bernardo has joined SeraCare’s board of directors in the role of Chairman. Mr. Bernardo is also an Operating Partner at Linden Capital Partners who are the equity investors behind SeraCare Life Sciences.

08/22/2017

SeraCare Enhances Quality Control Software

To ensure the accuracy of patient testing results, clinical next-generation sequencing (NGS) labs must track metrics across their assay’s workflow to determine whether runs were within established limits.